The Diagnostic Center For Disease 'Setting The Standard For Urology Excellence'

The Diagnostic Center for Disease(R) announces the Grand Opening of its World Headquarters in Sarasota, Florida scheduled for December 2006. The center offers the most advanced detection imaging technology and interpretation for prostate disease while featuring a 3.0 Tesla Signa HD-X Magnetic Resonance Imaging Spectroscopy (MRIS) scanner from General Electric, a world leader in image technology. The signature "Prostascan" image technology will provide a unique biochemical "finger print" of cancerous tissue (when present) as it evaluates the by- products of metabolism at the prostate cellular level.

"In effect, with my clinical experience, this scan will help us decode the disease, enabling better decisions and better treatment outcomes," states Dr. Ronald Wheeler, a Urologist and Medical Director for The Diagnostic Center for Disease. Peter Scardino, M.D., Medical Director of the Department of Urology at Memorial Sloan-Kettering (MSK) has been quoted as saying, "this is the next greatest advancement in prostate cancer diagnostic testing," where the accuracy of diagnosis versus the most aggressive cancers is in excess of 85%. According to Hedvig Hricak, M.D., Chair of the Department of Radiology at MSK, "The MRIS is a non-invasive diagnostic technology that gives the patient and the doctor a clear road map for treatment while tailored to the individual patient; doing what is necessary and nothing more." In an age when prostate cancer is being over-treated in upwards of 50-60% of cases, this concept expects to alter the paradigm of medical practice. Candidates for this unique technology include men with a PSA blood test result greater than 1.0 ng/ml who want to avoid random biopsies; a process that is associated with a 70-80% failure rate, suggesting that many patients are asked to under-go an unnecessary procedure. In effect, for many men, this procedure will replace the traditional biopsy. Additional candidates include men who choose to live with their cancer using an active surveillance program like Chronic Disease Management. In this scenario, men will be assured that the disease is not advancing while the PSA remains stable. This technological breakthrough also makes sense for men who are monitoring precursor lesions to prostate cancer. Finally, this technology will assist physicians in making improved decisions regarding the best treatment for the disease relevant to organ confinement assuring better outcome data.

The Diagnostic Center for Disease
http://www.mrisprostatecancercenter.com